GLP-1 Agonism Stimulates Browning of Subcutaneous White Adipose Tissue in Obesity Men
NCT ID: NCT02170324
Last Updated: 2017-01-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
20 participants
INTERVENTIONAL
2014-06-30
2015-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The extrapancreatic actions of glucagon-like peptide-1 (GLP-1) on endothelial cells and the liver have been reported. Additionally, effects of GLP-1 on adipose tissue have been described. Studies performed in isolated adipocytes have demonstrated that GLP-1 has the ability to induce both lipogenic and lipolytic mechanisms in white adipose tissue (WAT) . More recent study showed that GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMP-activated protein kinase (AMPK) in animal. However, there is no data clearly show that GLP-1 agonism stimulates browning of subcutaneous white adipose tissue (SWAT) in human obesity.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese Patients
NCT03671733
Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.
NCT05419726
Effects of GLP-1 Receptor Agonist on Fat Redistribution and Inflammatory Status
NCT02118376
Therapeutic Effects and Effects on Body Fat of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes for 1-4 Years
NCT05990374
The Efficacy and Safety of Liraglutide on Body Weight Loss in Obese and Overweight Patients
NCT04605861
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
GLP-1 agonism group
Exenatide injection 10 ug twice daily for 10 days subcutaneously.
Exenatide
Placebo group
0.9 % sodium choride 0.1 ml twice daily for 10 days subcutaneously.
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Exenatide
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Men
* Age 20 - 30 years old
Exclusion Criteria
* Diabetes
* Hypertension
* Use of medicines
20 Years
30 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Xiang Guang-da
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xiang Guang-da
Director of Endocrinology Dept.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Wuhan General Hospital
Wuhan, Hubei, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2014Wze091
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.